Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFκB pathways.

Item

http://www.wikidata.org/entity/Q35616605

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@ast

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@en

type

Item

label

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@ast

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@en

prefLabel

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@ast

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@en

P1476

Apolipoprotein CIII regulates ...... ia the MAPK and NFκB pathways.

@en

P2093

Daxin Pang

http://www.w3.org/2001/XMLSchema#string

Gangqi Wang

http://www.w3.org/2001/XMLSchema#string

Hongsheng Ouyang

http://www.w3.org/2001/XMLSchema#string

Jifeng Zhang

http://www.w3.org/2001/XMLSchema#string

Qi Song

http://www.w3.org/2001/XMLSchema#string

Tiedong Wang

http://www.w3.org/2001/XMLSchema#string

Xiaochun Tang

http://www.w3.org/2001/XMLSchema#string

Xiaolei Han

http://www.w3.org/2001/XMLSchema#string

Xingxing Liu

http://www.w3.org/2001/XMLSchema#string

Zhuang Li

http://www.w3.org/2001/XMLSchema#string

P2860

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women.

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.

Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2

Role of lysophosphatidylcholine (LPC) in atherosclerosis.

P304

661-665

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1242/BIO.201410900

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274396040

http://www.w3.org/2001/XMLSchema#string

P698

25836672

http://www.w3.org/2001/XMLSchema#string

P932

4434817

http://www.w3.org/2001/XMLSchema#string